The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndrome.
The effect of oral secoverine hydrochloride on neostigmine-stimulated sigmoid motility in 12 patients with irritable bowel syndrome was studied in a double-blind placebo-controlled cross-over study. Both spontaneous and stimulated motor activity were significantly reduced by the compound in comparison with placebo. The most sensitive indices were the frequency of wave activity, maximum amplitude and motility index. Two patients reported mild dizziness after secoverine.
D000293:Adolescent; D000328:Adult; D000368:Aged; D012809:Colon, Sigmoid / Q000502:physiology; D003109:Colonic Diseases, Functional / Q000503:physiopathology*; D003864:Depression, Chemical; D004311:Double-Blind Method; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000037:antagonists & inhibitors; D010276:Parasympatholytics / Q000009:adverse effects / Q000494:pharmacology*; D010627:Phenethylamines / Q000009:adverse effects / Q000494:pharmacology*; D011897:Random Allocation
D010276:Parasympatholytics; D010627:Phenethylamines; D009388:Neostigmine; C028187:secoverine